Article Details
Retrieved on: 2021-04-26 20:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche's Tecentriq and Merck's Keytruda will be under the microscope as the FDA convenes a multiday meeting to reconsider accelerated approvals ...
Article found on: www.fiercepharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here